Research Article Immunotherapy in dMMR/MSI-High Locally Advanced Rectal Cancer: Living in A New Era of Therapy
by Rodrigo Motta-Guerrero1, Monica Calderon-Anticona1,2*, Paola Montenegro3, Federico Esteso4, Jesus C Fabregas5
1Instituto Nacional de Enfermedades Neoplásicas. Lima, Perú.
2Instituto de Investigaciones en Ciencias Biomédicas, Universidad Ricardo Palma. Lima, Perú.
3Oncosalud. Lima, Perú.
4Instituto Alexander Fleming. Buenos Aires, Argentina.
5Memorial Healthcare System. Florida, United States.
*Corresponding author: Calderon-Anticona M, Instituto Nacional de Enfermedades Neoplásicas. Lima, Perú.
Received Date: 18 August, 2026
Accepted Date: 31 August, 2026
Published Date: 04 September, 2026
Citation: Motta-Guerrero R, Calderon-Anticona M, Montenegro P, Esteso F, Fabregas JC (2026) Immunotherapy in dMMR/MSI-High Locally Advanced Rectal Cancer: Living in A New Era of Therapy. J Oncol Res Ther 11: 10354. DOI: 10.29011/2574-710X.10354
Abstract
Colorectal cancer has the third highest incidence worldwide and rectal cancer comprises approximately 30% of all cases. Approximately, 339,022 direct deaths from rectal cancer were reported during 2020. Locally advanced rectal cancer has a trimodal approach which consists of chemotherapy, radiation and mesorectal excision. However, almost the half of patients eventually relapse, the 50% of them locoregionally. Total neoadjuvant regimen incorporates induction chemotherapy prior to chemoradiation for achieving high pathological complete response rates. Immunotherapy is an option of treatment that has been evaluated in colorectal cancer with positive results. Recently, several clinical trials have evaluated the benefit of immunotherapy in locally advanced rectal cancer, with interesting results, but controversial. The aim of this review is to evaluate the actual role of immunotherapy in the treatment of LARC.
Key Words: Immunotherapy; Rectal Cancer; Rectal tumor; Chemoradiotherapy.
© by the Authors & Gavin Publishers. This is an Open Access Journal Article Published Under Attribution-Share Alike CC BY-SA: Creative Commons Attribution-Share Alike 4.0 International License. Read More About Open Access Policy.